Southern Shuanglin Bio-Pharmacy completes regulatory rectification

Southern Shuanglin Bio-Pharmacy (SZSE:000403) has announced the completion of its rectification measures in response to an administrative regulatory decision issued by the Shanxi Securities Regulatory Bureau in May 2025. The issues identified pertained to the signing of supplemental agreements with customers and promoters by a subsidiary, without proper internal controls, resulting in inaccurate information disclosure.